Residency · Residency · Infectiousdisease

Febrile Neutropenia

Definitions and Risk Stratification

Core Definitions

Neutropenia is defined as an absolute neutrophil count below 500 cells per cubic millimeter, or an ANC below 1,000 cells per cubic millimeter with a predicted decline to below 500 within 48 hours. Fever in the neutropenic patient is defined as a single oral temperature of 38.3 degrees Celsius (101 degrees Fahrenheit) or above, or a sustained temperature of 38.0 degrees Celsius (100.4 degrees Fahrenheit) or above over one hour. Profound neutropenia refers to an ANC below 100 cells per cubic millimeter, while prolonged neutropenia denotes an expected duration exceeding seven days and places the patient in a high-risk category.

Risk Stratification -- MASCC Score

The Multinational Association for Supportive Care in Cancer score is the standard tool for risk stratification in febrile neutropenia. The score assigns a maximum of 26 points based on variables including the burden of illness (categorized as mild, moderate, or severe), the absence of hypotension, the absence of COPD, the presence of a solid tumor or the absence of a prior fungal infection, the absence of dehydration, outpatient status at fever onset, and age younger than 60 years. A MASCC score of 21 or above identifies low-risk patients with a mortality below 5 percent, who may be candidates for outpatient oral antibiotic therapy. A score below 21 identifies high-risk patients requiring hospital admission and intravenous therapy.

CISNE Score (Clinical Index of Stable Febrile Neutropenia)

The CISNE score provides additional risk discrimination among patients already classified as low risk by the MASCC score, identifying those who may still require hospitalization despite an apparently favorable initial risk assessment. Variables include an ECOG performance status of 2 or above, stress hyperglycemia, COPD, chronic cardiovascular disease, mucositis of NCI grade 2 or above, and a monocyte count below 200.

High-Risk Features

High-risk features in febrile neutropenia include an expected ANC below 100 for more than seven days, as typically seen in AML induction chemotherapy and allogeneic HSCT conditioning regimens. Additional high-risk features include significant comorbidities such as hemodynamic instability, pneumonia, new abdominal pain, and neurologic changes, as well as grade 3 to 4 mucositis, catheter-related infection, hepatic or renal insufficiency, and uncontrolled underlying cancer.

Initial Evaluation

Workup

The initial evaluation of febrile neutropenia must proceed rapidly and systematically. Blood cultures consisting of at least two sets, drawn from peripheral venipuncture and each lumen of any central line, must be obtained before antibiotics are administered. A complete blood count with differential, basic metabolic panel, hepatic function panel, and serum lactate should be obtained. Urinalysis and urine culture should be sent even in the absence of urinary symptoms. Chest radiography is indicated if respiratory symptoms are present, and CT of the chest should be obtained if there is high suspicion for invasive pulmonary aspergillosis. Additional cultures should be directed by symptoms: stool testing for C. difficile and bacterial pathogens if diarrhea is present, wound and skin cultures as appropriate, and lumbar puncture if meningeal signs are detected. Critically, antibiotics must not be delayed for culture results. Cultures should be drawn and antibiotics started immediately thereafter.

Biomarkers

Procalcitonin may assist in identifying bacterial infection when values exceed 0.5 nanograms per milliliter, but it cannot reliably exclude infection in neutropenic patients and should not be used in isolation for clinical decisions. Serial galactomannan testing performed twice weekly during neutropenia in high-risk patients enables early detection of invasive aspergillosis. 1,3-beta-D-glucan serves as a screening tool for invasive fungal infections broadly.

<image>A clinical risk stratification and initial management algorithm for febrile neutropenia. Start with "Fever ≥38.3°C + ANC <500." Step 1: "Immediate workup: blood cultures (peripheral + central line), CBC, BMP, LFTs, lactate, UA/UCx, CXR if respiratory symptoms." Step 2: "Risk Stratify (MASCC Score)." Branch: "MASCC ≥21 (Low Risk)" leading to "Consider outpatient PO antibiotics: ciprofloxacin + amoxicillin-clavulanate" with requirements listed (tolerating PO, reliable follow-up, no comorbidities, expected short neutropenia). "MASCC <21 (High Risk)" leading to "Admit: IV empiric anti-pseudomonal beta-lactam within 60 minutes." Below high-risk: list empiric options: "Cefepime 2g q8h, Meropenem 1g q8h, Piperacillin-tazobactam 4.5g q6h (extended infusion)." Include modifications: "+Vancomycin if: skin/catheter infection, hemodynamic instability, known MRSA, mucositis with fluoroquinolone prophylaxis." Use a clinical pathway format with color-coded risk levels.</image>

Empiric Antibiotic Therapy

Anti-Pseudomonal Monotherapy (Standard of Care)

The standard empiric approach to febrile neutropenia is anti-pseudomonal monotherapy. Cefepime at 2 grams intravenously every eight hours is the most commonly used agent, offering AmpC stability and anti-pseudomonal activity. Meropenem at 1 gram intravenously every eight hours provides the broadest spectrum and should be reserved for severe presentations, patients with MDR risk factors, or as an alternative after beta-lactam allergy test dosing. Piperacillin-tazobactam at 4.5 grams intravenously every six hours as an extended infusion provides anaerobic coverage and is particularly useful when an intra-abdominal source is suspected. Monotherapy has been shown to be as effective as combination therapy in meta-analyses, which confirm no benefit from routinely adding an aminoglycoside. Imipenem-cilastatin is an alternative carbapenem option, though it carries a higher seizure risk than meropenem.

When to Add Vancomycin/Anti-MRSA

Vancomycin should not be added routinely to the empiric regimen. Specific indications for adding vancomycin include suspected catheter-related infection, skin or soft tissue infection, known MRSA colonization, hemodynamic instability or septic shock, pneumonia, and severe mucositis in a patient receiving fluoroquinolone prophylaxis. If vancomycin is started empirically, it should be reassessed at 48 to 72 hours and discontinued if no MRSA is identified and the patient remains clinically stable.

When to Add Anaerobic Coverage

Anaerobic coverage should be added when intra-abdominal symptoms are present, including abdominal pain, diarrhea, and perianal symptoms. Piperacillin-tazobactam and carbapenems already provide anaerobic coverage. If cefepime is the empiric agent, metronidazole should be added for suspected intra-abdominal or perianal sources.

Modifications for MDR Risk

For patients with risk factors for ESBL-producing organisms, meropenem is the preferred empiric agent, particularly if there is prior ESBL colonization or infection. For CRE risk, options include ceftazidime-avibactam for KPC producers, meropenem-vaborbactam, or cefiderocol. For VRE risk, as seen in liver transplant patients, linezolid or daptomycin should be added.

Management of Persistent Fever

Fever >72-96 Hours Without Source

When fever persists for more than 72 to 96 hours without an identified source, the evaluation should be intensified with repeat blood cultures, CT of the chest to evaluate for invasive pulmonary aspergillosis including halo sign and nodules, CT of the sinuses, and CT of the abdomen. The empiric antibiotic regimen should not be routinely changed if the patient remains clinically stable, as persistent fever may reflect drug fever, tumor fever, or an unidentified viral cause. Evaluation for invasive fungal infection should include galactomannan, beta-D-glucan, CT of the chest, and consideration of bronchoalveolar lavage.

Empiric Antifungal Therapy

In high-risk patients with persistent fever after four to seven days of broad-spectrum antibiotics, empiric antifungal therapy should be initiated. Options include caspofungin at 70 milligrams intravenously as a loading dose followed by 50 milligrams daily, which provides empiric coverage against both Candida and Aspergillus, or liposomal amphotericin B at 3 milligrams per kilogram per day, or voriconazole if there is high Aspergillus suspicion and the patient is not already receiving azole prophylaxis. An alternative pre-emptive approach uses a biomarker-guided strategy combining serial galactomannan testing with CT of the chest rather than empiric antifungal initiation, which reduces unnecessary antifungal use and has been shown to be non-inferior to the empiric approach in studies such as Maertens 2010. Patients receiving posaconazole or voriconazole prophylaxis who develop breakthrough fever should be switched to a different antifungal class, either an echinocandin or amphotericin, as azole-resistant Aspergillus or Mucorales must be considered.

Prophylaxis in Neutropenic Patients

Antibacterial Prophylaxis

Fluoroquinolone prophylaxis with levofloxacin 500 milligrams daily during expected neutropenia exceeding seven days, as seen in AML induction and HSCT, reduces bacterial infections and febrile episodes, though a survival benefit remains debated. The risks include C. difficile infection, fluoroquinolone resistance, and selection of resistant organisms. Fluoroquinolone prophylaxis is not recommended for patients with expected short neutropenia of less than seven days or solid tumor patients.

Antifungal Prophylaxis

Posaconazole at 300 milligrams orally or intravenously daily is the standard antifungal prophylactic agent for AML induction and allogeneic HSCT recipients with GVHD, as demonstrated by the Cornely 2007 and Ullmann 2007 trials, which showed reductions in invasive aspergillosis and mortality. Micafungin at 50 milligrams intravenously daily serves as an alternative in HSCT patients who cannot tolerate azoles. Fluconazole at 400 milligrams daily prevents invasive candidiasis but does not prevent aspergillosis and is used in some lower-risk transplant settings.

Antiviral Prophylaxis

Acyclovir or valacyclovir provides HSV and VZV prophylaxis during chemotherapy and for at least one year post-HSCT, with longer durations for patients with ongoing immunosuppression or GVHD. Letermovir at 480 milligrams daily, or 240 milligrams with concurrent cyclosporine, provides CMV prophylaxis in CMV-seropositive allogeneic HSCT recipients through day 100 post-transplant. Letermovir does not cover other herpesviruses and is specific to CMV prevention.

PCP Prophylaxis

Trimethoprim-sulfamethoxazole double-strength daily or three times weekly is administered to all allogeneic HSCT recipients until they are off immunosuppression with a CD4 count above 200, to autologous HSCT recipients for three to six months, and to patients receiving high-dose corticosteroids exceeding 20 milligrams prednisone equivalent for more than four weeks.

<image>A timeline-based prophylaxis and monitoring chart for a patient undergoing allogeneic HSCT. Show a horizontal timeline from "Conditioning chemotherapy" through "Day 0 (transplant)" to "Day +100" and "Day +365." Along the timeline, show parallel horizontal bars for each prophylaxis: "Levofloxacin (during neutropenia until engraftment)," "Posaconazole (AML induction, or during GVHD treatment)," "Fluconazole or Micafungin (alternative antifungal during neutropenia)," "Acyclovir (from conditioning through ≥1 year post-transplant)," "Letermovir (CMV prophylaxis Day 0 to Day +100)," "TMP-SMX (PCP prophylaxis: start at engraftment, continue until off immunosuppression)." Include monitoring checkpoints: "Twice-weekly galactomannan during neutropenia," "Weekly CMV PCR," "Blood cultures with any fever." Show the high-risk periods for specific infections: bacterial (pre-engraftment), fungal (prolonged neutropenia + GVHD), viral (post-engraftment, CMV/EBV reactivation). Use a Gantt chart-style timeline format.</image>

When to Discontinue Empiric Antibiotics

Clinically Documented Infection

When a specific infection has been identified, treatment should be administered for the standard duration appropriate to that infection, regardless of ANC recovery. For example, gram-negative bacteremia should be treated for at least 7 to 14 days even if the ANC recovers promptly.

Unexplained Fever (No Source Identified)

When no source of infection is identified and the ANC is recovering to 500 or above, antibiotics can be discontinued when the patient has been afebrile for 24 to 48 hours and the ANC is rising or recovered. When the ANC is not recovering but the patient is afebrile, the IDSA 2011 guidelines suggest continuing antibiotics until the ANC reaches 500, though practice varies and some clinicians stop antibiotics after 7 to 14 days if the patient is afebrile and clinically well. When fever persists and the ANC is not recovering, antibiotics and antifungal coverage should be continued with ongoing evaluation for an unidentified source.

Special Considerations

Neutropenic Enterocolitis (Typhlitis)

Neutropenic enterocolitis, or typhlitis, represents inflammation and necrosis of the cecum and ascending colon during neutropenia. Patients present with fever, right lower quadrant pain, and diarrhea that may be bloody. CT findings include cecal wall thickening greater than 4 millimeters, pericecal fat stranding, and pneumatosis in severe cases. Treatment consists of bowel rest, intravenous broad-spectrum antibiotics such as meropenem or piperacillin-tazobactam, and surgical consultation for perforation or uncontrolled bleeding. G-CSF should be avoided until acute inflammation resolves due to the risk of perforation with rapid neutrophil recovery.

Perianal Infections

Perianal infections are common in neutropenic patients and may present with pain alone, with minimal erythema or fluctuance due to the absence of neutrophils to mount an inflammatory response. Rectal temperatures, rectal examinations, and suppositories should be avoided during neutropenia. Treatment requires broad-spectrum antibiotics covering gram-negatives and anaerobes, with surgical drainage deferred until ANC recovery.

Key Clinical Pearls

• Empiric antibiotics must be administered within 60 minutes of fever onset in neutropenic patients -- delays increase mortality
• Anti-pseudomonal monotherapy (cefepime, meropenem, or pip-tazo) is the standard empiric approach -- do NOT routinely add vancomycin or aminoglycosides
• Vancomycin should be added only for specific indications (catheter infection, hemodynamic instability, MRSA risk, severe mucositis) and re-evaluated at 48-72 hours
• Pre-emptive antifungal strategy (biomarker + CT-guided) is a valid alternative to empiric antifungal therapy for persistent fever
• Posaconazole prophylaxis is the standard of care for AML induction and GVHD -- it reduces invasive aspergillosis and all-cause mortality
• Letermovir has transformed CMV prevention in allogeneic HSCT -- administered through day +100
• Neutropenic enterocolitis (typhlitis) is a surgical emergency if perforation occurs -- maintain high clinical suspicion for RLQ pain during neutropenia

References

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011;52(4):e56-e93.
2. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043-3054.
3. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29(5):415-420.
4. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359.
5. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81-89.

Read this lecture as Markdown